BPG is committed to discovery and dissemination of knowledge
Featured Articles
1/21/2025 9:40:07 AM | Browse: 55 | Download: 105
Publication Name World Journal of Clinical Oncology
Manuscript ID 101766
Country China
Received
2024-09-25 15:02
Peer-Review Started
2024-09-25 15:02
To Make the First Decision
Return for Revision
2024-10-24 02:21
Revised
2024-11-06 03:25
Second Decision
2024-12-09 02:40
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief
2024-12-09 09:00
Articles in Press
2024-12-09 09:00
Publication Fee Transferred
2024-11-07 14:50
Edit the Manuscript by Language Editor
Typeset the Manuscript
2025-01-13 01:44
Publish the Manuscript Online
2025-01-21 09:22
ISSN 2218-4333 (online)
Open Access Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Case Report
Article Title Furmonertinib re-challenge for epidermal growth factor receptor-mutant lung adenocarcinoma after osimertinib-induced interstitial lung disease: A case report
Manuscript Source Unsolicited Manuscript
All Author List Fei-Fei Wei, Jing Zhang, Zhe Jia, Zhi-Chao Yao and Chun-Qiao Chen
Funding Agency and Grant Number
Funding Agency Grant Number
Guangxi Guilin Science and Technology Fund 20190218-7-6
Corresponding Author Chun-Qiao Chen, MD, Department of Oncology, People’s Hospital of Guilin, No. 12 Wenming Road, Guilin 541002, Guangxi Zhuang Autonomous Region, China. chencq8302@163.com
Key Words Furmonertinib; Osimertinib; Lung adenocarcinoma; Interstitial lung disease; Case report
Core Tip We report a case of a 56-year-old woman who was diagnosed with lung adenocarcinoma with lung hilum, mediastinal lymph nodes and brain metastases (T4N3M1c stage IVB). The patient received targeted treatment with osimertinib after radiotherapy and chemotherapy, but she developed interstitial lung disease following osimertinib treatment. After active treatment, her lung injury improved. The patient was retreated with furmonertinib combined with prednisone and did not experience interstitial lung disease again. So far, she has survived for 14 months without disease progression. This study suggests that retreatment with furmonertinib under steroid coverage could be considered as an effective therapeutic option after careful risk-benefit assessment for patients with epidermal growth factor receptor-mutant lung adenocarcinoma.
Publish Date 2025-01-21 09:22
Citation <p>Wei FF, Zhang J, Jia Z, Yao ZC, Chen CQ. Furmonertinib re-challenge for epidermal growth factor receptor-mutant lung adenocarcinoma after osimertinib-induced interstitial lung disease: A case report. <i>World J Clin Oncol</i> 2025; 16(3): 101766</p>
URL https://www.wjgnet.com/2218-4333/full/v16/i3/101766.htm
DOI https://dx.doi.org/10.5306/wjco.v16.i3.101766
Full Article (PDF) WJCO-16-101766-with-cover.pdf
CARE Checklist–2016 101766-CARE-Checklist-2016.pdf
Manuscript File 101766_Auto_Edited_083409.docx
Answering Reviewers 101766-answering-reviewers.pdf
Audio Core Tip 101766-audio.m4a
Conflict-of-Interest Disclosure Form 101766-conflict-of-interest-statement.pdf
Copyright License Agreement 101766-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s) 101766-foundation-statement.pdf
Signed Consent for Treatment Form(s) or Document(s) 101766-informed-consent-statement.pdf
Non-Native Speakers of English Editing Certificate 101766-non-native-speakers.pdf
Peer-review Report 101766-peer-reviews.pdf
Scientific Misconduct Check 101766-scientific-misconduct-check.png
Scientific Editor Work List 101766-scientific-editor-work-list.pdf
CrossCheck Report 101766-crosscheck-report.pdf